SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[Sinovac Reports Preliminary Top-Line Results from Phase III Clinical Trial for EV71 Vaccine Candidate Against Hand, Foot and Mouth Disease -- Unblinded Phase III Preliminary Results Demonstrate Vaccine Efficacy Rate of 95.4% SVA BEIJING, March 14, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. ( ir@sinovac.com scarrington@theruthgroup.com aestrada@theruthgroup.com] [Sinovac Schedules Conference Call and Webcast for Fourth Quarter and Full Year Unaudited Financial Results Beijing – April 2, 2013 – Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of vaccines in China, today announced that it will release its unaudited financial results for the fourth quarter and full year ended December 31, 2012, before market on Thursday, April 18,] [Sinovac Receives Commercial Approval in Mexico for Seasonal Flu Vaccine SVA Beijing – April 18, 2013 – Sinovac Biotech Ltd. (Nasdaq: Dr. Weidong Yin, Chairman, President and CEO of Sinovac, said, “ This is a great milestone for Sinovac as we look to continue expanding our commercial efforts worldwide. We are pleased to receive approval to supply Anflu in the] [Sinovac EV71 Vaccine Phase III Top-Line Results Presented at 13th Annual World Vaccine Congress & Expo – Efficacy and Safety Data for EV71 Vaccine Discussed in Presentation by Deputy Director of Jiangsu Provincial CDC Beijing – April 18, 2013 – Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of vaccines in China,announced today that Fengcai Zhu, Deputy Director of the] [Sinovac Reports Unaudited Fourth Quarter and Full Year 2012 Financial Results – Conference call scheduled for Thursday, April 18, 2013 at 8:00 AM EDT– – Sinovac Biotech Ltd. ( today its unaudited fourth quarter and full year Beijing – April 18, 2013 Financial Highlights l Total sales were $19.0 million for the fourth quarter of 2012, a decrease of 10.4%] []

By | 2016-03-24T00:41:44+00:00 May 3rd, 2013|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments
Read More

SVA [SINOVAC BIOTECH] 20-F: (Original Filing)

[None (Title of Class) Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report. 55,091,561 common shares as of December 31, 2012 o Yes x No o Yes x No x Yes o No x Yes o No Large accelerated filer] [SINOVAC BIOTECH LTD. ARTICLE 1. PURPOSE Plan Company The purpose of the Sinovac Biotech Ltd. 2012 Share Incentive Plan (the “ ARTICLE 2. DEFINITIONS AND CONSTRUCTION Wherever the following terms are used in the Plan they shall have the meanings specified below, unless the context clearly indicates otherwise. The singular pronoun shall include the plural where the context so indicates.] [SUPPLEMENTAL AGREEMENT TO A LEASE CONTRACT Party A Lessor: China Bioway Biotech Group Co., Ltd. (hereinafter referred to as “ Party B Lessee: Sinovac Biotech Co., Ltd. (hereinafter referred to as “ Original Lease Contract WHEREAS, Party A and Party B signed a lease contract on August 12, 2004, under which Party A leased its No.2 Factory located in the] [SUPPLEMENTAL AGREEMENT TO A LEASE CONTRACT Party A Lessor: China Bioway Biotech Group Co., Ltd. (hereinafter referred to as “ Party B Lessee: Sinovac Biotech Co., Ltd. (hereinafter referred to as “ Original Lease Contract WHEREAS, Party A and Party B signed a lease contract on June 4, 2007, under which Party A leased its No.1 Factory located in the] [SUPPLEMENTAL AGREEMENT TO A LEASE CONTRACT Lessor Party A: China Bioway Biotech Group Co., Ltd. (the “ Original Lessee Party B: Sinovac Biotech Co., Ltd. (the “ New Lessee Party C: Beijing Sinovac R&D Technology Co., Ltd. (the “ Original Contract Based on the principles of equality and mutual benefit, Party A, Party B and Party C hereby enter into] [SUPPLEMENTAL AGREEMENT TO A LEASE CONTRACT Party A Lessor: China Bioway Biotech Group Co., Ltd. (hereinafter referred to as “ Party B Lessee: Beijing Sinovac R&D Technology Co., Ltd. (hereinafter referred to as “ Sinovac Beijing Original Lease Contract WHEREAS, Party A, Party B and Sinovac Biotech Co., Ltd. (hereinafter referred to as “ 1. Both parties agree that the] [List of Subsidiaries 1. Sinovac Biotech (Hong Kong) Ltd., a Hong Kong company 2. Tangshan Yian Biological Engineering Co., Ltd., a PRC company 3. Sinovac Biotech Co., Ltd., a PRC company 4. Sinovac Research and Development Co., Ltd. (formerly known as Beijing Sinovac Biological Technology Co., Ltd.), a PRC company 5. Sinovac (Dalian) Vaccine Technology Co., Ltd., a PRC company] [Certification by the Chief Executive Officer I, Weidong Yin, certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [Certification by the Chief Financial Officer I, Danny Chung, certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [Certification by the Chief Executive Officer 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. EX-13.1 10 a13-4096_1ex13d1.htm EX-13.1] [Certification by the Chief Financial Officer 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. EX-13.2 11 a13-4096_1ex13d2.htm EX-13.2] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-161827) pertaining to the 2003 Stock Option Plan of Sinovac Biotech Ltd., of our reports dated April 29, 2013, with respect to the consolidated financial statements of Sinovac Biotech Ltd. and the effectiveness of internal control over financial reporting]

By | 2016-03-24T00:44:20+00:00 April 30th, 2013|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments
Read More

SVA [SINOVAC BIOTECH] 20-F: None (Title of Class) Indicate the number of

[None (Title of Class) Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report. 55,091,561 common shares as of December 31, 2012 o Yes x No o Yes x No x Yes o No x Yes o No Large accelerated filer] [SINOVAC BIOTECH LTD. ARTICLE 1. PURPOSE Plan Company The purpose of the Sinovac Biotech Ltd. 2012 Share Incentive Plan (the “ ARTICLE 2. DEFINITIONS AND CONSTRUCTION Wherever the following terms are used in the Plan they shall have the meanings specified below, unless the context clearly indicates otherwise. The singular pronoun shall include the plural where the context so indicates.] [SUPPLEMENTAL AGREEMENT TO A LEASE CONTRACT Party A Lessor: China Bioway Biotech Group Co., Ltd. (hereinafter referred to as “ Party B Lessee: Sinovac Biotech Co., Ltd. (hereinafter referred to as “ Original Lease Contract WHEREAS, Party A and Party B signed a lease contract on August 12, 2004, under which Party A leased its No.2 Factory located in the] [SUPPLEMENTAL AGREEMENT TO A LEASE CONTRACT Party A Lessor: China Bioway Biotech Group Co., Ltd. (hereinafter referred to as “ Party B Lessee: Sinovac Biotech Co., Ltd. (hereinafter referred to as “ Original Lease Contract WHEREAS, Party A and Party B signed a lease contract on June 4, 2007, under which Party A leased its No.1 Factory located in the] [SUPPLEMENTAL AGREEMENT TO A LEASE CONTRACT Lessor Party A: China Bioway Biotech Group Co., Ltd. (the “ Original Lessee Party B: Sinovac Biotech Co., Ltd. (the “ New Lessee Party C: Beijing Sinovac R&D Technology Co., Ltd. (the “ Original Contract Based on the principles of equality and mutual benefit, Party A, Party B and Party C hereby enter into] [SUPPLEMENTAL AGREEMENT TO A LEASE CONTRACT Party A Lessor: China Bioway Biotech Group Co., Ltd. (hereinafter referred to as “ Party B Lessee: Beijing Sinovac R&D Technology Co., Ltd. (hereinafter referred to as “ Sinovac Beijing Original Lease Contract WHEREAS, Party A, Party B and Sinovac Biotech Co., Ltd. (hereinafter referred to as “ 1. Both parties agree that the] [List of Subsidiaries 1. Sinovac Biotech (Hong Kong) Ltd., a Hong Kong company 2. Tangshan Yian Biological Engineering Co., Ltd., a PRC company 3. Sinovac Biotech Co., Ltd., a PRC company 4. Sinovac Research and Development Co., Ltd. (formerly known as Beijing Sinovac Biological Technology Co., Ltd.), a PRC company 5. Sinovac (Dalian) Vaccine Technology Co., Ltd., a PRC company] [Certification by the Chief Executive Officer I, Weidong Yin, certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [Certification by the Chief Financial Officer I, Danny Chung, certify that: 1. I have reviewed this annual report on Form 20-F of Sinovac Biotech Ltd. (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [Certification by the Chief Executive Officer 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. EX-13.1 10 a13-4096_1ex13d1.htm EX-13.1] [Certification by the Chief Financial Officer 2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. EX-13.2 11 a13-4096_1ex13d2.htm EX-13.2] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-161827) pertaining to the 2003 Stock Option Plan of Sinovac Biotech Ltd., of our reports dated April 29, 2013, with respect to the consolidated financial statements of Sinovac Biotech Ltd. and the effectiveness of internal control over financial reporting]

By | 2016-03-24T00:45:22+00:00 April 30th, 2013|Categories: Chinese Stocks, SVA, Webplus ver|Tags: , , , , , |0 Comments
Read More

WX [WuXi PharmaTech (Cayman)] 20-F: (Original Filing)

[WuXi PharmaTech (Cayman) Inc. Page INTRODUCTION 1 2 PART I. ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS 3 ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE 3 ITEM 3. KEY INFORMATION 3 ITEM 4. INFORMATION ON THE COMPANY 26 ITEM 4A. UNRESOLVED STAFF COMMENTS 46 ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS 46 ITEM 6. DIRECTORS, SENIOR MANAGEMENT] [LIST OF SUBSIDIARIES • WuXi AppTec (BVI) Inc., incorporated in British Virgin Islands; • WuXi AppTec Co., Ltd., incorporated in People’s Republic of China (“PRC”); • WuXi AppTec (Shanghai) Co., Ltd., incorporated in PRC; • Shanghai SynTheAll PharmaTech Co., Ltd., incorporated in PRC; • WuXi AppTec (Suzhou) Co., Ltd., incorporated in PRC; • WuXi AppTec (Tianjin) Co., Ltd. , incorporated] [Certification by the Chief Executive Officer I, Ge Li, certify that: 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered] [Certification by the Chief Financial Officer I, Edward Hu, certify that: 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered] [Section 906 of the Sarbanes-Oxley Act of 2002 Ge Li Chief Executive Officer EX-13.1 5 d414832dex131.htm EX-13.1] [Certification by the Chief Financial Officer Edward Hu Chief Financial Officer EX-13.2 6 d414832dex132.htm EX-13.2] [April 17, 2013 WuXi PharmaTech (Cayman) Inc. 288 Fute Zhong Road Waigaoqiao Free Trade Zone Shanghai 200131 People’s Republic of China RE: WUXI PHARMATECH (CAYMAN) INC. Dear Sirs/Madams, Company We have acted as legal advisors as to the laws of the People’s Republic of China to WuXi PharmaTech (Cayman) Inc., an exempted limited liability company incorporated in the Cayman Islands] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement No. 333-182917 on Form S-8 of our reports dated April 17, 2013, relating to the consolidated financial statements and financial statement schedule of WuXi PharmaTech (Cayman) Inc. and its subsidiaries, and the effectiveness of WuXi PharmaTech (Cayman) Inc. and its subsidiaries’ internal control]

By | 2016-04-02T17:10:00+00:00 April 17th, 2013|Categories: Chinese Stocks, SEC Original, WX|Tags: , , , , , |0 Comments
Read More

WX [WuXi PharmaTech (Cayman)] 20-F: WuXi PharmaTech (Cayman) Inc. Page INTRODUCTION 1 2

[WuXi PharmaTech (Cayman) Inc. Page INTRODUCTION 1 2 PART I. ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS 3 ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE 3 ITEM 3. KEY INFORMATION 3 ITEM 4. INFORMATION ON THE COMPANY 26 ITEM 4A. UNRESOLVED STAFF COMMENTS 46 ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS 46 ITEM 6. DIRECTORS, SENIOR MANAGEMENT] [LIST OF SUBSIDIARIES • WuXi AppTec (BVI) Inc., incorporated in British Virgin Islands; • WuXi AppTec Co., Ltd., incorporated in People’s Republic of China (“PRC”); • WuXi AppTec (Shanghai) Co., Ltd., incorporated in PRC; • Shanghai SynTheAll PharmaTech Co., Ltd., incorporated in PRC; • WuXi AppTec (Suzhou) Co., Ltd., incorporated in PRC; • WuXi AppTec (Tianjin) Co., Ltd. , incorporated] [Certification by the Chief Executive Officer I, Ge Li, certify that: 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered] [Certification by the Chief Financial Officer I, Edward Hu, certify that: 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered] [Section 906 of the Sarbanes-Oxley Act of 2002 Ge Li Chief Executive Officer EX-13.1 5 d414832dex131.htm EX-13.1] [Certification by the Chief Financial Officer Edward Hu Chief Financial Officer EX-13.2 6 d414832dex132.htm EX-13.2] [April 17, 2013 WuXi PharmaTech (Cayman) Inc. 288 Fute Zhong Road Waigaoqiao Free Trade Zone Shanghai 200131 People’s Republic of China RE: WUXI PHARMATECH (CAYMAN) INC. Dear Sirs/Madams, Company We have acted as legal advisors as to the laws of the People’s Republic of China to WuXi PharmaTech (Cayman) Inc., an exempted limited liability company incorporated in the Cayman Islands] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement No. 333-182917 on Form S-8 of our reports dated April 17, 2013, relating to the consolidated financial statements and financial statement schedule of WuXi PharmaTech (Cayman) Inc. and its subsidiaries, and the effectiveness of WuXi PharmaTech (Cayman) Inc. and its subsidiaries’ internal control]

By | 2016-04-02T17:10:52+00:00 April 17th, 2013|Categories: Chinese Stocks, Webplus ver, WX|Tags: , , , , , |0 Comments
Read More

BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)

[Biostar Pharmaceuticals, Inc. Reports 2012 Results XIANYANG, China, April 15, 2013 /PRNewswire/ -- Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced financial results for the full year ended December 31, 2012. SUMMARY FINANCIALS Full Year 2012]

By | 2016-03-03T11:12:34+00:00 April 16th, 2013|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments
Read More

BSPM [Biostar Pharmaceuticals,] 8-K: Biostar Pharmaceuticals, Inc. Reports 2012 Results XIANYANG, China,

[Biostar Pharmaceuticals, Inc. Reports 2012 Results XIANYANG, China, April 15, 2013 /PRNewswire/ -- Biostar Pharmaceuticals, Inc. (NASDAQ GM: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced financial results for the full year ended December 31, 2012. SUMMARY FINANCIALS Full Year 2012]

By | 2016-03-03T11:18:03+00:00 April 16th, 2013|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments
Read More

BSPM [Biostar Pharmaceuticals,] 8-K: (Original Filing)

[Biostar Pharmaceuticals, Reports 2012 Results XIANYANG, China, April 15, 2013 /PRNewswire/ -- Biostar Pharmaceuticals, (NASDAQ GM: BSPM) ("Biostar" or "thempany"), a-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases andnditions, today announced financial results for the full year ended December 31, 2012.]

By | 2016-02-07T15:22:53+00:00 April 16th, 2013|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments
Read More

BSPM [Biostar Pharmaceuticals,] 8-K: Biostar Pharmaceuticals, Reports 2012 Results XIANYANG, China, April

[Biostar Pharmaceuticals, Reports 2012 Results XIANYANG, China, April 15, 2013 /PRNewswire/ -- Biostar Pharmaceuticals, (NASDAQ GM: BSPM) ("Biostar" or "thempany"), a-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases andnditions, today announced financial results for the full year ended December 31, 2012.]

By | 2016-02-07T15:23:29+00:00 April 16th, 2013|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments
Read More

BSPM [Biostar Pharmaceuticals,] 10-K: (Original Filing)

[FORM 10-K (Mark One) x December 31, 2012 For the fiscal year ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 86-29-33686638 (Former name, former] [Product Research and Development Agreement Party A: Shaanxi Aoxing Pharmaceutical Co. Ltd. Party B: Life Science Academy of Northwest University Party A and Party B reached the following R&D agreement regarding National Type I new medicine Danshensu Borneol Ester through friendly negotiation: 2. Project research progress: (1) Party B has finished the research of DBZ’s activity, technical, quality standard and] [Consent of Independent Registered Public Accounting Firm To the Board of Directors of Biostar Pharmaceuticals, Inc. We hereby consent to the incorporation by reference in the Registration Statement on Forms S-8 (No. 333-161598) and S-8 (No. 333-183387) of Biostar Pharmaceuticals, Inc. of our report dated April 11, 2013 relating to the consolidated financial statements, which appears in the Annual Report] [CONSENT OF INDEPENDENT REGISTERED ACCOUNTING FIRM To the Board of Directors of Biostar Pharmaceuticals, Inc. Mazars CPA Limited Mazars CPA Limited Certified Public Accountants Hong Kong April 11, 2013 EX-23.2 4 ex23-2.htm] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION I, Qinghua Liu, certify that: 1. I have reviewed this annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Dated: April 15, 2013 Ronghua Wang Chief Executive Officer EX-32.1 7 ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Dated: April 15, 2013 Qinghua Liu Interim Chief Financial Officer (principal financial officer) EX-32.2 8 ex32-2.htm]

By | 2016-03-03T11:20:32+00:00 April 15th, 2013|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments
Read More
Skip to toolbar